PMID- 35181626
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20220405
IS  - 1550-8080 (Electronic)
IS  - 0091-7370 (Linking)
VI  - 52
IP  - 1
DP  - 2022 Jan
TI  - ROP-ESAT6-CFP10 as Tuberculosis-Specific Antigen in Interferon Gamma Release 
      Assay.
PG  - 126-132
AB  - OBJECTIVE: The ROP-ESAT6-CFP10 antigen (Changzhou Niujin Shisong Biotech [CBI], 
      China) was recently developed using recombinant overlapping peptide (ROP) 
      technology. We used ROP-ESAT6-CFP10 as a tuberculosis (TB)-specific antigen and 
      compared it with existing interferon-gamma release assays (IGRAs). METHODS: 
      Healthy volunteers and patients who were diagnosed with TB within a one-year 
      period were enrolled. Samples were tested with QuantiFERON-TB Gold (QFT; QIAGEN 
      Sciences Inc., USA), T-SPOT.TB (Oxford Immunotec, UK), and ELISpot using 
      ROP-ESAT6-CFP10 as a TB-specific antigen (ROP-TB). For ROP-TB, two concentrations 
      (1 mug and 5 mug) of ROP-ESAT6-CFP10 were used as TB-specific antigens. Agreement 
      between assays was evaluated. RESULTS: A total of 35 TB patients and 20 healthy 
      volunteers were evaluated. Agreement between T-SPOT.TB and ROP-TB 1 mug, QFT and 
      ROP-TB 1 mug, and ROP-TB 1 mug and ROP-TB 5 mug/mL were 79.1% (kappa=0.483), 76.7% 
      (kappa=0.557), and 95.3% (kappa=0.894), respectively. The median number of spots 
      between the T-SPOT.TB and ROP-TB assays in the TB patients had no significant 
      difference. CONCLUSIONS: ELISpot using newly developed ROP-ESAT6-CFP10 showed 
      good agreement with T-SPOT.TB and QFT. Since ROP technology can lower the 
      manufacturing cost, ROP-ESAT6-CFP10 might work as a good source of TB-specific 
      antigen for IGRAs.
CI  - Copyright (c) 2022 by the Association of Clinical Scientists, Inc.
FAU - Kim, Moon Jung
AU  - Kim MJ
AD  - Department of Laboratory Medicine, Myongji Hospital, Hanyang University Medical 
      Center, Goyang, Korea.
FAU - Ha, Eun-Hye
AU  - Ha EH
AD  - Division of Pulmonary and Critical Care Medicine, Myongji Hospital, Hanyang 
      University Medical Center, Goyang, Korea.
FAU - Lee, Young-Kwan
AU  - Lee YK
AD  - MJCELL-BIO Inc., Research and Development Center, Goyang, Korea.
FAU - Park, Sang Joon
AU  - Park SJ
AD  - Division of Pulmonary and Critical Care Medicine, Myongji Hospital, Hanyang 
      University Medical Center, Goyang, Korea.
FAU - An, Chang Hyeok
AU  - An CH
AD  - Division of Pulmonology, Department of Internal Medicine, Hanil General Hospital, 
      Seoul, Korea.
FAU - Park, So-Yeon
AU  - Park SY
AD  - Department of Rheumatology, Myongji Hospital, Hanyang University Medical Center, 
      Goyang, Korea.
FAU - Kim, Soo-Kyung
AU  - Kim SK
AD  - Department of Laboratory Medicine, Myongji Hospital, Hanyang University Medical 
      Center, Goyang, Korea skkim1@ewha.ac.kr.
AD  - Department of Laboratory Medicine, Ewha Womans University College of Medicine, 
      Seoul, Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Clin Lab Sci
JT  - Annals of clinical and laboratory science
JID - 0410247
RN  - 0 (Antigens, Bacterial)
SB  - IM
MH  - Antigens, Bacterial
MH  - China
MH  - Humans
MH  - Interferon-gamma Release Tests
MH  - *Latent Tuberculosis/diagnosis
MH  - *Mycobacterium tuberculosis
MH  - Tuberculin Test
MH  - *Tuberculosis/diagnosis
OTO - NOTNLM
OT  - Interferon gamma release assay
OT  - Latent tuberculosis infection
OT  - Overlapping peptide
EDAT- 2022/02/20 06:00
MHDA- 2022/04/05 06:00
CRDT- 2022/02/19 05:29
PHST- 2022/02/19 05:29 [entrez]
PHST- 2022/02/20 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
AID - 52/1/126 [pii]
PST - ppublish
SO  - Ann Clin Lab Sci. 2022 Jan;52(1):126-132.